Miltenyi Biotec, Inc. Acquires Medic Tools AG

BERGISCH GLADBACH, Germany, June 10 /PRNewswire/ -- Miltenyi Biotec has acquired Medic Tools AG from Zug, Switzerland. With this acquisition, Miltenyi Biotec strengthens the portfolio in the area of sample preparation. "The innovative and high-quality devices and techniques fit perfectly into the product range of instruments, reagents, and services offered by Miltenyi Biotec", Miltenyi Biotec CEO Dr. Boris Stoffel and Franz G. Bucher, Vice President and CEO of Medic Tools AG, stated in a conjoint announcement.

As a first result of the previous cooperation, the gentleMACS(TM) Dissociator was introduced into the market several months ago. The instrument facilitates the generation of single-cell suspensions from tissues and thus, helps generate the ideal starting material for the separation and isolation of specific cell types using MACS(R) Technology. This procedure to separate cells magnetically was developed by Miltenyi Biotec and is a research laboratory standard worldwide.

The additional expertise of Medic Tools enables Miltenyi Biotec to further engage in development projects in the area of sample preparation. "We offer our biomedical research customers a complete solution", adds Dr. Stoffel, "from sample preparation to cell separation, cell analysis, cytological and molecular analysis."

The involved parties agreed that financial details of the transaction should not be disclosed.

About Miltenyi Biotec

The company is one of the largest and most successful biotechnology companies in Germany. More than 1,100 employees develop, produce and sell products for biomedical research and clinical applications. The renowned MACS Technology for magnetic separation of cells has become a standard technology in research laboratories worldwide.

CONTACT: Contact: Prof. Dr. Uwe Heinlein, Corporate Communications,
Miltenyi Biotec GmbH, Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach,
Germany, Phone +49-2204-8306-6590, E-mail uweh@miltenyibiotec.de,
http://www.miltenyibiotec.com

Back to news